Tremelimumab,Durvalumab 
Astrazeneca
[]
infinity: neoadjuvant durvalumab plus tremelimumab in gastric/gej cancer with msi-h #gi23 15 evaluable pts, preoperative t300/d 3-mos pcr 60%
mpr 80% g 3 ae 3/18 pcr rate t4 tumor 17%, t2-3 tumors 89% 
MD, Associate Professor, Medical Oncologist. Deputy Editor at @OfOncological. #breastcancer #colorectalcancer #lungcancer #precisionmedicine #HealthForAll